All In Biotech

Drug Trial Radar · NCT07343635

The Efficacy and Safety of Anti-inflammation Treatment (Hirudoid Introduction Followed by Yellow Light Therapy) Combined With Tofacitinib and Doxycycline in Chinese Adult Patients With Mild to Moderate Erythematous Telangiectatic Rosacea

The Efficacy and Safety of Anti-inflammation Treatment (Hirudoid Introduction Followed by Yellow Light Therapy) Combined With Tofacitinib and Doxycycline in Chinese Adult Patients With Mild to Moderate Erythematous Telangiectatic Rosacea: A Prospective Parallel Controlled Single-blind Cohort Study

Last checked: Nov 20, 2026Latest source record: Mar 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

186

Planned (sponsor's estimate)

Start

Feb 1, 2026

Primary completion

Jul 1, 2027

Study completion Jul 1, 2027

Sponsor

Sponsor type
Academic, hospital or other
First posted
Jan 15, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Non randomized
Model
Parallel
Masking
Double (investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The efficacy and safety of anti-inflammation treatment (Hirudoid introduction followed by yellow light therapy) combined with tofacitinib and doxycycline in Chinese adult patients with mild to moderate erythematous telangiectatic rosacea: A prospective parallel controlled single-blind cohort study

Conditions

  • Erythematotelangiectatic Rosacea

Interventions

  • DoxycyclineDrug

    Doxycycline 100 mg orally once daily

  • HydroxychloroquineDrug

    Hydroxychloroquine 200 mg orally twice daily.

  • TofacitinibDrug

    Tofacitinib 5mg orally twice daily.

  • Anti-inflammatory Treatment (Hirudoid Introduction Followed by Yellow Light Therapy)Device

    Topical application of Hirudoid followed by yellow light therapy (wavelength 590 nm, duration 20 minutes per session, once weekly)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Achievement of IGA treatment success at Week 12Time frame: 0 week、12 week

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The Fourth Affiliated Hospital of Zhejiang University School of Medicine

    Yiwu, Zhejiang, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.